EL PASO HEALTH

Mental Health Clinical Practice Guidelines Follow up After Hospitalization for Mental Illness The following guideline provides recommendations for members 6 years of age and older who were hospitalized for treatment of mental illness or intentional self-harm and who had a follow up visit with a mental health practitioner. A follow up visit with a mental Outpatient visit with mental health practitioner health practitioner within 7 or • A community mental health center visit with a mental health practitioner 30 days after discharge, not to • A telehealth or telephone visit with a mental health practitioner include visits on date of • An observation visit with a mental health practitioner discharge. Any of the following • Transitional care management services with a mental health provider meets criteria: • Psychiatric collaborative care management Electroconvulsive therapy Follow up care for Children Prescribed ADHD Medication The following guideline provides recommendations for members 6 to 12 years of age that have been newly prescribed ADD and/or ADHD disorder medications. (Applies if member didn't have any ADHD medications dispensed [new or refill prescriptions] 120 days prior to new prescription start date.) A follow up visit with a Outpatient visit practitioner with prescribing Observation visit authority within 30 days after Health and behavior assessment/intervention the dispensing date for the ADHD medication. Any of the · Community mental health center visit following meets criteria: Telehealth or Telephone visit At least two follow up visits Outpatient visit with any practitioner from 31 to • Observation visit 270 days after the dispensing Health and behavior assessment/intervention date for the ADHD medication. • Community mental health center visit Any of the following meets • Telehealth or Telephone visit criteria: • E-visit or virtual check-in (only one of the 2 visits may be an e-visit or virtual check-in) Dexmethylphenidate Lisdexamfetamine Methamphetamine Guanfacine ADHD Medications Dextroamphetamine Methylphenidate Clonidine Atomoxetine These guidelines are based on the HEDIS 2022 Performance Measures. Individual patient considerations and advances in medical science may

These guidelines are based on the HEDIS 2022 Performance Measures. Individual patient considerations and advances in medical science may supersede or modify these recommendations.

Rev: 08/05/2022

EPHP0820209 QIC Approved: 07/30/2020